News
NEWS

  • news

Selected for UTokyo IPC 1st Round.

Celaid Therapeutics has been selected as a support candidate for UTokyo IPC 1st Round (3rd). The program aims to provide entrepreneurial support to teams and companies aiming at social implementation utilizing technological seeds related to the University of Tokyo. With the support of UTokyo IPC, we will proceed with commercialization.

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2022 All Rights Reserved Powered by STINGER.